People: Venaxis Inc (APPY.PH)

APPY.PH on Philadelphia Stock Exchange

1.78USD
14 May 2013
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.78
Open
$1.78
Day's High
$1.78
Day's Low
$1.78
Volume
100
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Gail Schoettler

 68 2010 Non-Executive Independent Chairman of the Board

Stephen Lundy

 50 2010 President, Chief Executive Officer, Director

Jeffrey McGonegal

 61 2010 Chief Financial Officer, Corporate Secretary

Donald Hurd

 2012 Senior Vice President, Chief Commercial Officer

Greg Pusey

 2012 Vice President

Susan Evans

 56 2013 Independent Director

Daryl Faulkner

 63 2010 Independent Director

John Landon

 71 2008 Independent Director

David Welch

 65 2004 Independent Director

Stephen Williams

 2013 Independent Director
» Insider Trading

Biographies

Name Description

Gail Schoettler

 Ambassador Dr. Gail S. Schoettler is Non-Executive Independent Chairman of the Board of AspenBio Pharma Inc. She has served on the board of AspenBio Pharma, Inc., since August 2001. She is a member of the audit committee and the nominating and governance committee of AspenBio Pharma, Inc. In October of 2010, Ms. Schoettler became Non-Executive Chair of the board of AspenBio. She also serves on the board and is a member of the audit committee of Delta Dental of Colorado, a privately held dental benefits company. She serves on the boards of The Colorado Trust, where she chairs the investment committee, and several non-profit organizations. Former corporate board positions include; Masergy Communications, Inc., CancerVax, Inc., PepperBall Technologies, Inc., AirGate PCS, Women's Bank, Equitable Bancshares of Colorado, and Fischer Imaging. She has served as a U.S. Ambassador, appointed by President Clinton, and as Colorado's Lt. Governor and State Treasurer. In 1998, she narrowly lost her bid for Governor of Colorado. She started two banks and helps run her family's cattle ranch (where she grew up), vineyards, and real estate enterprises. She and her husband own a travel company that focuses on introducing business and community leaders to their counterparts overseas as well as to other countries' cultures, economies, and history. She earned a BA in economics from Stanford and MA and PhD degrees in African History from the University of California at Santa Barbara. Among her numerous awards is the French Legion of Honor (France's highest civilian award) from President Jacques Chirac of France.

Stephen Lundy

 Mr. Stephen T. Lundy is President, Chief Executive Officer, Director of AspenBio Pharma Inc. since March 24, 2010. Effective on the same date, he was appointed to the Company's Board of Directors. Mr. Lundy has more than 20 years of experience in drug and diagnostic product development and commercialization. He most recently was Chief Executive Officer of MicroPhage from 2008 to 2010. Mr. Lundy was Senior VP of sales and marketing for Vermillion from 2007 to 2008. Mr. Lundy joined Vermillion from GeneOhm (2003-2007), a division of Becton, Dickinson and Company Diagnostics, where he served as Vice President of Sales and Marketing. At GeneOhm, Mr. Lundy led the commercial launch of several novel molecular diagnostic assays including the first molecular test for Methicillin resistant Staphylococcus aureus. From 2002 to 2003, Mr. Lundy served as Vice President of Marketing for Esoterix, Inc., which was acquired by Laboratory Corporation of America, and he led the commercial integration and re-branding of the numerous reference labs acquired by Esoterix. Prior to Esoterix, he served as Marketing Director for Molecular Diagnostics and Critical Care Testing at Bayer Diagnostics Corporation. Mr. Lundy graduated from the United States Air Force Academy with a Bachelor of Science and was an officer with the United States Air Force from 1983 to 1988.

Jeffrey McGonegal

 Mr. Jeffrey G. McGonegal is Chief Financial Officer, Corporate Secretary of AspenBio Pharma Inc. He became Chief Financial Officer of the Company in June 2003, was appointed Corporate Secretary in January 2010 and served as interim President in December 2004 and January 2005. Mr. McGonegal served from 2003 to January 1, 2011 as Chief Financial Officer of PepperBall Technologies, Inc. Mr. McGonegal also serves on a limited part-time basis as Senior Vice President — Finance of Cambridge Holdings, Ltd., a small publicly held company with limited business activities. Mr. McGonegal served as Chief Financial Officer of Bactolac Pharmaceutical, Inc. and had been associated with its predecessors through October 2006, a company (publicly held until September 2006) engaged in manufacturing and marketing of vitamins and nutritional supplements. From 1974 to 1997, Mr. McGonegal was an accountant with BDO Seidman LLP. While at BDO Seidman LLP, Mr. McGonegal served as Managing Partner of the Denver, Colorado office. Until his resignation on March 21, 2012, Mr. McGonegal was elected in 2005 to serve on the board of Imagenetix, Inc., a publicly held company in the nutritional supplements industry. He received a B.A. degree in Accounting from Florida State University.

Donald Hurd

 Mr. Donald R. Hurd is the Senior Vice President and Chief Commercial Officer of AspenBio Pharma, Inc. Mr. Hurd has more than 30 years of experience with in vitro diagnostic companies and joins AspenBio from BioBehavioral Diagnostics, where he most recently served as Vice President Sales. Prior positions include: Vice President Marketing/Sales at MicroPhage; Vice President North American Customer Operations, Siemens Healthcare Diagnostics; and U.S. Director of Sales, Bayer Healthcare Diagnostics. Mr. Hurd received a Bachelor of Science in Business Administration and was in the military with the United States Navy.

Greg Pusey

 Mr. Gregory S. Pusey is Vice President of AspenBio Pharma Inc. He resigned as Director of the Company, effective 26 September 2012. Throughout his involvement with AspenBio, he has assisted with financings, transactions and strategic matters. Over the years Mr. Pusey has served AspenBio in a number of different capacities. Mr. Pusey is a director and assistant secretary of Bactolac Pharmaceutical, Inc., a privately held company engaged in manufacturing and marketing of vitamins and nutritional supplements. Since 1988, Mr. Pusey has been the President and a director of Cambridge Holdings, Ltd. which has distributed almost all of its assets and has limited activities. Until his resignation in April 2011, Mr. Pusey had served as a director of PepperBall Technologies, Inc. and its predecessors, since 2002. Over the last 35 years, Mr. Pusey has helped a variety of companies with corporate development and financing activities. Mr. Pusey graduated from Boston College with a Bachelor of Science degree in Finance.

Susan Evans

 Dr. Susan A. Evans, Ph.D., FACB, has been appointed as Independent Director of Venaxis, Inc., effective January 1, 2013. She brings 30 years of experience in diagnostics and laboratory medicine. She serves currently as Vice President, Scientific Affairs for the Beckman Coulter division of Danaher Inc. Dr. Evans has been with Beckman Coulter since 2006, where she held past roles as Vice President, Corporate Strategic Planning and Vice President/General Manager of Beckman Coulter Genomics, known formerly as Agencourt Bioscience. Prior to her career at Beckman Coulter, Dr. Evans held senior product development and R&D positions at Caliper Life Sciences and LifeScan, respectively. Dr. Evans began her career in diagnostics at Dade Behring, Inc., where she served in various R&D capacities from 1981 – 2000, eventually assuming a leadership role as Senior Vice President of R&D. Dr. Evans is also a Past President, Secretary, and member of Board of Directors for the American Association of Clinical Chemistry (AACC), for which she received an award in 2008 for contributions through service to the profession. She currently Chairs the Van Slyke Foundation Board of Trustees as well as the Awards Committee for AACC. Dr. Evans earned a Ph.D. in chemistry from the University of Detroit.

Daryl Faulkner

 Mr. Daryl Jay Faulkner is Independent Director of AspenBio Pharma Inc. He was appointed to the Company's Board of Directors in the newly created position of Executive Chairman on January 19, 2009 and on February 10, 2009, was appointed to serve as the Company's interim Chief Executive Officer. Mr. Faulkner resigned from the positions of interim Chief Executive Officer as of March 24, 2010, upon the hiring of Mr. Lundy and the position of Chairman in October 2010. He continues to serve as a director of the company. Mr. Faulkner has more than 25 years experience in developing and commercializing medical devices, drug and drug delivery systems, life science research tools, and molecular diagnostics. He served for approximately one year as President, CEO and a member of the Board of Directors of Digene Corporation, a Nasdaq-traded company prior to its acquisition in July 2007 by Qiagen (traded on Nasdaq's Global Select market). He served as a consultant to Qiagen, and as co-chair of the executive integration steering committee with the CEO of Qiagen from July 2007 to January 2009. Currently, Mr. Faulkner also serves as a member of the Board of Directors of GenMark Diagnostics, Inc. (Nasdaq:GNMK), an emerging molecular diagnostics company traded on Nasdaq. Prior to joining Digene, Mr. Faulkner spent eight years with Invitrogen (now Nasdaq:LIFE) in a number of senior roles, including SVP Europe, SVP IVGN International Operations, and SVP of Strategic Business Units. Before Invitrogen, Mr. Faulkner's career includes 15 years with the Fortune 100 Company, Abbott Laboratories, in which he held leadership positions in manufacturing operations and plant management. Mr. Faulkner received a degree in Industrial Relations from the University of North Carolina and a M.A. in Business Management from Webster University.

John Landon

 Mr. John H. Landon is an Independent Director of AspenBio Pharma Inc., since December 2008. He is a member of the compensation and nominating and corporate governance committees for AspenBio Pharma, Inc. Mr. Landon's career includes more than 30 years of broad, multi-functional experience with the DuPont Company. Prior to retiring from active management, Mr. Landon served as Vice President and General Manager of medical products for DuPont. He had worldwide responsibility for all of DuPont's medical product businesses, encompassing total annual sales of $1 billion and more than 5,000 employees. In addition to other director roles, Mr. Landon served as Chairman of the board of Cholestech Corporation prior to its 2007 sale to Inverness Medical and as a director of Digene Corporation prior to its 2007 sale to Qiagen. He currently is a member of the board of LipoScience, Inc., a trustee of Christiana Care Health System, and an advisor to Water Street Healthcare Partners. Mr. Landon received his B.S. in Chemical Engineering from the University of Arizona.

David Welch

 Mr. David E. Welch is an Independent Director of AspenBio Pharma Inc., since October 2004. Mr. Welch is chair of the AspenBio Pharma audit committee. Mr. Welch has served since April 2004 as Vice President and Chief Financial Officer of American Millennium Corporation, Inc., a private company (publicly traded until June 2010) located in Golden, Colorado. Mr. Welch formerly served as a director of PepperBall Technologies, Inc. He also is a self-employed financial consultant. From July 1999 to June 2002, Mr. Welch served as Chief Financial Officer, Secretary and Treasurer of Active Link Communications, Inc., another publicly traded company. During 1998, he served as Chief Information Officer for Language Management International, Inc., a multinational translation firm located in Denver, Colorado. From 1996 to 1997, he was Director of Information Systems for Mircromedex, Inc., an electronic publishing firm, located in Denver, Colorado. Mr. Welch also serves on the Board of Directors of Communication Intelligence Corporation, a publicly traded company. He received a B.S. degree in accounting from the University of Colorado. Mr. Welch is a Certified Public Accountant, licensed in the state of Colorado.

Stephen Williams

 Dr. Stephen A. Williams, M.D., Ph.D., has been appointed as Independent Director of Venaxis, Inc., effective May 1, 2013. Dr. Williams joined SomaLogic in 2009 as Chief Medical Officer. Prior to his time at SomaLogic, Dr. Williams trained as a physician at Charing Cross and Westminster Medical School, University of London, and following his internships, returned to the same institution for a Ph.D. in medicine and physiology. He subsequently performed three years of residency in diagnostic imaging at the University of Newcastle upon Tyne. In 1989 he joined Pfizer U.K. in experimental medicine and worked on a variety of programs including asthma, irritable bowel syndrome, migraine [eletriptan], depression [sertraline] and urinary incontinence [darifenacin]. He moved to the U.S. in 1993 with Pfizer and worked on programs in inflammatory bowel disease, stroke, psychosis [ziprasidone] and head injury. He created the clinical technology group in 1997, which became a worldwide function on five research sites with the objective of validating clinical biomarkers and measurements, and was named vice president in 2006. Dr. Williams served on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering from 2004-2007 and the executive Committee of the Biomarkers Consortium run by the Foundation for NIH from 2005-2007. In process initiatives, he led or co-led initiatives in diagnostics, biomarkers, quality of drug candidates, and guidelines for development teams to make the decision to start Phase 3 trials.

Basic Compensation

Name Fiscal Year Total

Gail Schoettler

 --

Stephen Lundy

 577,517

Jeffrey McGonegal

 270,148

Donald Hurd

 --

Greg Pusey

 261,190

Susan Evans

 --

Daryl Faulkner

 450,961

John Landon

 --

David Welch

 --

Stephen Williams

 --
As Of 30 Dec 2011

Insider Trading

Name Shares Traded Price

HURD DONALD R

 15,000 $1.99

SCHOETTLER GAIL S

 2,500 $1.58

PUSEY GREGORY S

 2,000 $1.94

LUNDY STEPHEN T

 4,000 $1.93

MERSON MICHAEL R

 1,000 $1.92

MCGONEGAL JEFFREY G

 5,000 $1.92

MCGONEGAL JEFFREY G

 3,625 $1.58
» Full list on Insider Trading
Search Stocks